請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80251完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 廖述朗(Shu-Lang Liao) | |
| dc.contributor.author | Yen-Yi Chen | en |
| dc.contributor.author | 陳彥伊 | zh_TW |
| dc.date.accessioned | 2022-11-24T03:03:17Z | - |
| dc.date.available | 2021-08-30 | |
| dc.date.available | 2022-11-24T03:03:17Z | - |
| dc.date.copyright | 2021-08-30 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-07-07 | |
| dc.identifier.citation | 1.Arcaini L, Burcheri S, Rossi A, et al. 2007. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 18:346–350. 2.Arnaud P, Escande MC, Lecuit M, et al. 2007. Hepatitis C virus infection and MALT-type ocular adnexal lymphoma. Ann Oncol 18(2):400–401. 3.Amrita Desai, Madhura G. Joag, et al. 2017. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood. 129(3):324-332 4.Chan CC, Smith JA, Shen DF, et al. 2004. Helicobacter pylori (H. pylori) molecular signature in conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma. Histopathol 19(4):1219-26. 5.Chen MH, Hsiao LT, Chiou TJ, et al. 2008. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol 87(6): 475-480. 6.Cohen VM, Sweetenham J, Singh AD. 2008. Ocular adnexal lymphoma. What is the evidence for an infectious aetiology? Br J Ophthalmol. 92:446–448. 7.Coupland SE. 2013. Molecular pathology of lymphoma. Eye 27(2), 180-189. 8.Chuang SS, Lee C, Hamoudi RA, Liu H, Lee PS, Ye H et al. 2003. High frequency of t (11; 18) in gastric mucosa‐associated lymphoid tissue lymphomas in Taiwan, including one patient with high‐grade transformation. British journal of haematology 120(1), 97-100 9.Desai A, Joag MG, Lekakis L, et al. 2017. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood 129(3):324-332. 10.Esmaeli B, Sniegowski M. et al. 2015. Orbital and ocular adnexal lymphoma. Orbital Tumors: Diagnosisand Treatment 145–153 11.Felipe A Castro, Lina Jansen et al 2015. Survival of patients with gastric lymphoma in Germany and in the United States. J Gastroenterol Hepatol. 30(10):1485-91 12.Ferreri AJ, Guidoboni M, Ponzoni M, et al. 2004. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96(8):586-94. 13.Ferreri AJ, Ponzoni M, Viale E,et al. 2006. Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. Hematol Oncol 24(1):33-37. 14.Ferreri AJ, Viale E, Guidoboni M, et al. 2006. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol 17(5):769–772 15.Frederik Holm, Lauge Hjorth Mikkelsen et al. 2020. Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017. Br J Ophthalmol 0:1–7 16.Freeman C, Berg JW, Cutler SJ. 1972. Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260. 17.Graue GF, Finger PT, Maher E, et al. 2013. Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor. Eur J Ophthalmol. 23(3):344e55 18.Han JJ, Kim TM, Jeon YK, et al. 2015. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol. 94(4):575e81 19.Hooi James KY, Lai WY, Ng WK, et al. 2017. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 153(2): 420-429. 20.Hui Yu, Yu-Xin Du et al. 2019 Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China. Int J Ophthalmol 12:1731-1736 21.Jenkins C, Rose GE, Bunce C, et al. 2000. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 84(8):907-913 22.Jenkins C, Rose GE, Bunce C, et al. 2003. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye 17(7):809-820. 23.Kasem Seresirikachorn, Lalita Norasetthada et al. 2018 Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand. Blood research 53: 307-313 24.Kaustubh Mulay, Santosh G Honavar et al. 2016. An update on ocular adnexal lymphoma. Seminarsin Diagnostic Pathology 33: 164–172 25.Kazuki Tanimoto, Akihiro Kaneko et al. 2007 Primary Ocular Adnexal MALT Lymphoma: A Long-term Follow-up Study of 114 Patients. Jpn J Clin Oncol 37(5)337–344 26.Kirkegaard MM, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF. 2016. Conjunctival lymphoma—an international multicenter retrospective study. Jama Ophthalmology, 134(4), 406-414. 27.Lee JL, Kim MK, Lee KH, et al. 2005. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 84(1):13-18. 28.Lee SB, Yang JW, Kim CS. 2008. The association between conjunctival MALT lymphoma and Helicobacter pylori. Br J Ophthalmol 92(4):534–536. 29.Lee SE, Paik JS, Cho WK, et al. 2011. Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Am J Hematol. 2011;86(3):262-266 30.Marina M. Kirkegaard, Sarah E. Coupland et al. 2015. Malignant lymphoma of the conjunctiva. Survey of Ophthalmology 30: 444-458 31.Marcucci F, Spada E, Mele A, et al. 2012. The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma–a review. Am J Blood Res 2(1): 18. 32.Michael T. Yen et al. 2018. Treatments for ocular adnexal lymphoma: A report by American Academy of Ophthalmology. Ophthalmology 125:127-136 33.Moslehi R, Devesa SS, Schairer C, et al. 2006. Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst 98: 936-939 34.Moslehi Roxana F, Bruce C, and Maria J. Schymura 2011. Descriptive epidemiology of ophthalmic and ocular adnexal non-Hodgkin’s lymphoma. Expert Rev Ophthalmol 6(2): 175-180. 35.Mu-Chen Zhanga, Min Zhoub et al. 2019. Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases. Lung Cancer 132: 39–44 36.Oh, Dong-Eun, and Yoon-Duck Kim 2007. Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol 125(12): 1668-1673 37.Olsen TG, Holm, F, Mikkelsen L.H. et al. 2019. Orbital lymphoma—an international multicenter retrospective study. Am J Ophthalmol 199: 44-57. 38.Olsen, TG, and Steffen H. 2019. Orbital lymphoma. Surv Ophthalmol 64(1): 45-66. 39.Ohtsuka K, Hashimoto M, Suzuki Y. 2004. High incidence of orbital malignant lymphoma in Japanese patients. Am J Ophthalmol 138(5): 881–882. 40.Osama M Ahmed, Anthony K Ma et al. 2020. Epidemiology, outcomes, and prognostic factors of orbital lymphoma in the United States Orbit 39(6):397-402 41.Pasquale Ferraro, Victor F. Trastek,et.al. 2000. Primary Non-Hodgkin’s Lymphoma of the Lung. Ann Thorac Surg 69:993–7 42.Pei-Hsuan Lin, Yoshiyuki Kitaguchi et al. 2017. Bilateral orbital marginal zone B-cell lymphoma of the mucosaassociated lymphoid tissue in a patient with hepatitis B virus infection. American Journal of Ophthalmology Case Reports 7:27-30 43.Sjö, Lene Dissing. 2009. Ophthalmic lymphoma: epidemiology and pathogenesis. Acta Ophthalmol 87: 1-20. 44.Spencer J, Wotherspoon AC. 1997. Gastric MALT lymphoma and Helicobacter pylori. Cancer Surv. 30:213-231. 45.Strianese D, Tranfa, F, Finelli, M et al. 2010. Hepatitis C virus infection in ocular adnexal lymphomas. Arch Ophthalmol 128(10): 1295-1299. 46.Sullivan TJ, Grimes D, Bunce I. 2004. Monoclonal antibody treatment of orbital lymphoma. Ophthalmic Plast Reconstruct Surg. 20:103–106 47.Svendsen FH, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF. 2017. Lymphoma of the Eyelid–An International Multicenter Retrospective Study. American Journal of Ophthalmology, 177, 58-68. 48.Tine Gadegaard Olsen, Frederik Holm et al. 2019. Orbital Lymphoma—An International Multicenter Retrospective Study. Am J Ophthalmol 199:44–57 49.Tine Gadegaard Olsen, MD, 2019. Orbital lymphoma, survey of ophthalmology 64: 45-66 50.Verdijk RM. 2017. Lymphoproliferative Tumors of the Ocular Adnexa. Asia Pac J Ophthalmol (Phila) 6(2):132e42 51.Xiaowu Li, Xiang Wang et al. 2016. Evaluation of the clinical characteristics, management,and prognosis of 103 patients with gastricmucosa-associated lymphoid tissue lymphoma. Oncology Letters 11:1713-1718 52.Yu H, Du YX, Sun ZC, et al. 2019. Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China. Int J Ophthalmol 12(11): 1731. 53.Zschoche M, Zimpfer A, Scheef BO, Jünemann AM, Guthoff RF, Junghanss C. 2020. Histopathological Features and Ann Arbor Stage in Periocular Lymphoma. In Vivo, 34(4), 1965-1974. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80251 | - |
| dc.description.abstract | 目的: 比較台灣地區族群跟西方族群的眼窩及眼周淋巴癌之流行病學表現及預後預測因子。 方法: 以蒐集病歷資料的方式回溯過去從1985年01月到2019年12月在台大醫院就醫的眼窩及眼周淋巴癌病人資料。納入條件(Inclusion criteria)包括經過手術取樣組織病理診斷的眼窩及眼周淋巴癌，並且追蹤時間至少6個月以上。排除條件(Exclusion criteria)包括其他非淋巴癌的眼窩及眼周腫瘤以及發炎性疾病，像是甲狀腺眼疾或是第四型免疫球蛋白G相關的眼病變(IgG4-related ophthalmic disease)等等。人口統計訊息包括病歷所記載的年紀、性別、淋巴癌的次分類、腫瘤位置、腫瘤分期、治療方式都將進行統計分析。主要評估指標(primary endpoints)包括無疾病存活期(DSS)，整體存活期(OS)及疾病無惡化存活期(PFS)。 結果: 本次研究總共收錄了112位病人，平均發病的年齡為59.0 ± 15.5歲(範圍從23-92歲)，包括了59位男性(52.7%)及53位女性(47.3%)。大多數109位病人(97.3%)為B細胞淋巴癌，T細胞淋巴癌僅占3%。結節邊緣區型淋巴癌是其中最大宗，約76位病人(67.9%)，11人(9.8%)屬於瀰漫性大型B細胞淋巴癌、9人(8.0%)屬於濾泡性淋巴癌、6人(5.4%)屬於小淋巴球性淋巴癌、4人(3.6%)屬於被套細胞淋巴癌及其他種類。在腫瘤位置當中，最主要發生侵犯的位置為眼窩(44人，39.3%)，其次為結膜(31人，27.7%)，淚腺(27人，25%)，以及較少受到侵犯的眼瞼(8人，7.1%)。平均追蹤的期間為 89.5±72.3個月(範圍從6-342個月)，所有病人在5年及10年的無疾病存活期(DSS)分別為89.9%及81.6%; 在5年及10年的整體存活期(OS)分別為88.8%及78.0%; 在5年及10年的疾病無惡化存活期(PFS)分別為65.0%及56.2%。在預後預測因子分析的部分，病人年紀大於60歲、有高階較侵犯性淋巴癌、後期淋巴癌將有比較差之預後。 結論: 結節邊緣區型淋巴癌為在台灣地區最常見的眼窩及眼周淋巴癌種類，並且在台灣地區的比例也比西方國家要來的高。在比較年輕的病人(年紀<60歲)，較早期的眼周及眼窩淋巴癌(stage I and stage II)，及較低階的病理組織分類(結節邊緣區型淋巴癌(EMZL)、濾泡性淋巴癌(FL)、小淋巴球性淋巴癌(SLL))，病人的疾病相關生存期(DSS)預後較好。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-24T03:03:17Z (GMT). No. of bitstreams: 1 U0001-0607202112015300.pdf: 2456267 bytes, checksum: b7bfff4deec98d440e0b5f1196063b06 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | "目 錄 口試委員會審定書 i 誌謝 ii 中文摘要iii 英文摘要v 第一章 緒論 1 1.1眼窩及眼周淋巴癌簡介 1 1.2疾病診斷與治療 2 1.3 研究目的 3 第二章 研究方法 5 2.1 納入條件與排除條件 5 2.2 資料收集與診斷方式 5 2.3 分析統計 6 第三章 研究結果 7 3.1 流行病學與臨床表徵 7 3.2 腫瘤位置與症狀 8 3.3 治療方式與結果 8 3.4 預後因子分析 9 第四章 討論 11 4.1 流行病學 11 4.2 慢性抗原刺激 11 4.3 治療方式與結果 13 4.4 結節邊緣區型淋巴癌 14 4.5 研究限制 17 第五章 結論 18 參考文獻 19 圖 目 錄 Figure 1. Distribution of different histopathological subtypes 26 Figure 2. Distribution of lymphoma subtypes among anatomical locations 27 Figure 3. Treatment modalities of limited stage and advanced stage OAL 28 Figure 4. Treatment outcomes according to OAL subtypes at last follow-up 29 Figure 5. Treatment outcomes according to OAL stages at last follow-up 30 Figure 6. The Kaplan-Meier survival curves for DSS, OS and PFS of OAL 31 Figure 7. The Kaplan-Meier survival curves for DSS, OA and PFS for OAL in different period 32 Figure 8. DSS was not associated with radiation therapy or radiation dosage 33 Figure 9. DSS was significantly associated with different histopathological subtypes 34 Figure 10. The Kaplan-Meier survival curves for DSS according by different risk factors 35 表 目 錄 Table 1. Clinical features of patients with different histopathological features 36 Table 2. Distribution of lymphoma subtypes among anatomical locations 37 Table 3. Treatment modalities of limited stage and advanced stage OAL 38 Table 4. Treatment outcomes according to OAL subtypes at last follow-up 39 Table 5. Treatment outcomes according to OAL stages at last follow-up 40 Table 6. Univariate and multivariate analysis by Cox Proportional Hazards Model for DSS 41" | |
| dc.language.iso | zh-TW | |
| dc.subject | 預後存活 | zh_TW |
| dc.subject | 結節邊緣區型淋巴癌 | zh_TW |
| dc.subject | 黏膜相關淋巴組織型 | zh_TW |
| dc.subject | 眼周淋巴癌 | zh_TW |
| dc.subject | 放射線治療 | zh_TW |
| dc.subject | MALT lymphoma | en |
| dc.subject | Survival prognosis | en |
| dc.subject | Radiotherapy | en |
| dc.subject | EMZL | en |
| dc.subject | Extranodal marginal zone lymphoma | en |
| dc.subject | Ocular adnexal lymphoma | en |
| dc.title | 台灣地區眼窩及眼周淋巴癌之流行病學表現及預後預測因子 | zh_TW |
| dc.title | Demographic and prognostic factors of orbital and ocular adnexal lymphoma in Taiwan | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊偉勛(Hsin-Tsai Liu),陳偉勵(Chih-Yang Tseng) | |
| dc.subject.keyword | 結節邊緣區型淋巴癌,黏膜相關淋巴組織型,眼周淋巴癌,放射線治療,預後存活, | zh_TW |
| dc.subject.keyword | Extranodal marginal zone lymphoma,EMZL,Ocular adnexal lymphoma,MALT lymphoma,Radiotherapy,Survival prognosis, | en |
| dc.relation.page | 41 | |
| dc.identifier.doi | 10.6342/NTU202101291 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2021-07-08 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0607202112015300.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 2.4 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。